At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Not Yet Opened 01-12 16:00:00 EST
325.54
-0.56
-0.17%
盘后325.53
-0.01+0.00%
19:57 EST
High328.47Low322.74Vol2.46M
Open328.47D1 Closing326.10Amplitude1.76%
Mkt Cap175.30BTradable Cap174.81BTotal Shares538.48M
T/O799.88MT/O Rate0.46%Tradable Shares536.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Amgen's MariTide phase 2 study shows 'meaningful' reduction in blood sugar, weight
Reuters  ·  08:10
Amgen's MariTide phase 2 study shows 'meaningful' reduction in blood sugar, weight
Amgen Highlights Pipeline Advances and Growth Across Oncology, Rare Disease, Inflammation, and General Medicine in New Presentation
Reuters  ·  07:52
Amgen Highlights Pipeline Advances and Growth Across Oncology, Rare Disease, Inflammation, and General Medicine in New Presentation
Amgen: Second Year of Maritide Treatment Very Well Tolerated Including at Quarterly Doses, With Very Low Incidence of Nausea, Vomiting & No New Safety Signals Observed
THOMSON REUTERS  ·  07:49
Amgen: Second Year of Maritide Treatment Very Well Tolerated Including at Quarterly Doses, With Very Low Incidence of Nausea, Vomiting & No New Safety Signals Observed
Amgen: "Large Majority" of People in 52-Week Maritide Extension Study Given Lower Monthly Dose or Quarterly Dose of Drug Maintained Weight Loss Achieved in Part 1 of Phase 2 Trial
THOMSON REUTERS  ·  07:49
Amgen: "Large Majority" of People in 52-Week Maritide Extension Study Given Lower Monthly Dose or Quarterly Dose of Drug Maintained Weight Loss Achieved in Part 1 of Phase 2 Trial
Amgen: 24-Week Study of Monthly Maritide in People With Type 2 Diabetes Showed Robust, Clinically Meaningful Reduction in Both Hba1c, Weight
THOMSON REUTERS  ·  07:49
Amgen: 24-Week Study of Monthly Maritide in People With Type 2 Diabetes Showed Robust, Clinically Meaningful Reduction in Both Hba1c, Weight
Spyre Therapeutics Appoints Kate Tansey Chevlen as Chief Commercial Officer
Reuters  ·  01-12 21:01
Spyre Therapeutics Appoints Kate Tansey Chevlen as Chief Commercial Officer
How Amgen’s DISCO Oncology Licensing Deal Will Impact Amgen (AMGN) Investors
Simply Wall St.  ·  01-11 18:16
How Amgen’s DISCO Oncology Licensing Deal Will Impact Amgen (AMGN) Investors
Amgen Inc. Stock Underperforms Friday When Compared To Competitors
Dow Jones  ·  01-10
Amgen Inc. Stock Underperforms Friday When Compared To Competitors
Goldman Sachs Adjusts Price Target on Amgen to $403 From $400, Maintains Buy Rating
MT Newswires Live  ·  01-09
Goldman Sachs Adjusts Price Target on Amgen to $403 From $400, Maintains Buy Rating
Amgen Advances Leukemia Strategy With Completed Blinatumomab Study in Japan
TIPRANKS  ·  01-09
Amgen Advances Leukemia Strategy With Completed Blinatumomab Study in Japan
Amgen Inc : Truist Securities Raises Target Price to $319 From $318
THOMSON REUTERS  ·  01-08
Amgen Inc : Truist Securities Raises Target Price to $319 From $318
Call for Application for 2026 Tsinghua Amgen Scholars Program
prnewswire  ·  01-08
Call for Application for 2026 Tsinghua Amgen Scholars Program
Amgen Shares Rise After Upgrade From UBS
MT Newswires Live  ·  01-08
Amgen Shares Rise After Upgrade From UBS
Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs
Benzinga  ·  01-08
Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs
Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up 5%; Eli Lilly Rises 4% to Record High; Amgen up 3%; Roche, Novo up Around 2%
Tiger Newspress  ·  01-07
Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up 5%; Eli Lilly Rises 4% to Record High; Amgen up 3%; Roche, Novo up Around 2%
UBS Upgrades Amgen to Buy From Neutral, Raises Price Target to $380 From $317
MT Newswires Live  ·  01-07
UBS Upgrades Amgen to Buy From Neutral, Raises Price Target to $380 From $317
Amgen Coverage Assumed by UBS at Buy vs Previous Rating of Neutral
Dow Jones  ·  01-07
Amgen Coverage Assumed by UBS at Buy vs Previous Rating of Neutral
Disco Pharmaceuticals: Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies With Amgen
THOMSON REUTERS  ·  01-07
Disco Pharmaceuticals: Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies With Amgen
Disco Pharmaceuticals: Disco Will Be Eligible to Receive up to $618 Mln Total Potential Deal Value Plus Royalties
THOMSON REUTERS  ·  01-07
Disco Pharmaceuticals: Disco Will Be Eligible to Receive up to $618 Mln Total Potential Deal Value Plus Royalties
UBS Raises Amgen (AMGN.US) Target to $380: Two Pipeline Drugs Expected to Drive Growth Through 2030
Stock News  ·  01-07
UBS Raises Amgen (AMGN.US) Target to $380: Two Pipeline Drugs Expected to Drive Growth Through 2030

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Issue price:
--